- Home
- TRU vs ILMN Comparison
TRU vs ILMN Comparison
Compare TRU & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRU
- ILMN
- Stock Information
- Founded
- TRU 1968
- ILMN 1998
- Country
- TRU United States
- ILMN United States
- Employees
- TRU N/A
- ILMN N/A
- Industry
- TRU Finance: Consumer Services
- ILMN Medical Specialities
- Sector
- TRU Finance
- ILMN Health Care
- Exchange
- TRU Nasdaq
- ILMN Nasdaq
- Market Cap
- TRU 18.0B
- ILMN 15.9B
- IPO Year
- TRU 2015
- ILMN 2000
- Fundamental
- Price
- TRU $72.89
- ILMN $71.20
- Analyst Decision
- TRU Buy
- ILMN Buy
- Analyst Count
- TRU 12
- ILMN 18
- Target Price
- TRU $113.91
- ILMN $139.50
- AVG Volume (30 Days)
- TRU 2.7M
- ILMN 2.6M
- Earning Date
- TRU 04-24-2025
- ILMN 05-08-2025
- Dividend Yield
- TRU 0.63%
- ILMN N/A
- EPS Growth
- TRU N/A
- ILMN N/A
- EPS
- TRU 1.45
- ILMN N/A
- Revenue
- TRU $4,183,800,000.00
- ILMN $4,372,000,000.00
- Revenue This Year
- TRU $6.00
- ILMN $0.09
- Revenue Next Year
- TRU $10.44
- ILMN $4.71
- P/E Ratio
- TRU $50.27
- ILMN N/A
- Revenue Growth
- TRU 9.20
- ILMN N/A
- 52 Week Low
- TRU $66.07
- ILMN $68.70
- 52 Week High
- TRU $113.17
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- TRU 40.32
- ILMN 34.18
- Support Level
- TRU $69.11
- ILMN $68.70
- Resistance Level
- TRU $76.38
- ILMN $76.16
- Average True Range (ATR)
- TRU 4.81
- ILMN 4.18
- MACD
- TRU -0.05
- ILMN 0.38
- Stochastic Oscillator
- TRU 32.88
- ILMN 17.78
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries, and about a quarter of its revenue comes from international markets.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.